Home > Back to Publisher > Report Information

Monoclonal Antibodies: A Segment of Major Growth

CHI Insight Pharma Reports
March 1, 2011
SKU: CHI6169277

Abstract Table of Contents Related Reports

Monoclonal antibodies are highly valuable therapeutic agents and were among the best-selling drugs in the world in 2010. Global revenues from monoclonal antibody products will have moved significantly past the $40 billion level in 2010 and are poised to continue growing steadily through to 2015.

Discussed in this report:

Nearly 300 monoclonal antibodies currently in clinical development,
organized by indication and/or target
Sales of currently marketed monoclonal antibodies, market share by
company, and projected market growth
Anticipated filing dates for prospective products and their commercial prospects
Threats such as reimbursement constraints and the emergence of
biosimilar products
Enabling and emerging technologies for optimization of therapeutic
monoclonal antibodies
Corporate profiles of monoclonal antibody product-focused and technologyfocused
companies

Executive Sumary
Chapter 1
INTRODUCTION: 1.1. Introduction; 1.2. Regulatory Background; 1.3. Technology Background
Chapter 2
KEY TECHNOLOGIES: 2.1. Introduction; 2.2. Murine-Derived Monoclonal; 2.3. Chimeric Monoclonal Antibodies; 2.4. Humanized Monoclonal Antibodies; 2.5. Fully Human Monoclonal Antibodies; 2.6. Antibody Fragments; 2.7. Modified Antibodies
Chapter 3
COMMERCIALIZED MONOCLONAL
ANTIBODIES: 3.1. Overview; 3.2. Oncology Therapeutics; 3.3. Inflammatory and Autoimmune; 3.4. Other Indications; 3.5. Labeled Antibodies
Chapter 4
MONOCLONAL ANTIBODIES IN THE PIPELINE: ONCOLOGY: 4.1. Introduction; 4.2. Antibodies in Advanced Development; 4.3. Antibodies in Phase II Development; 4.4. Early-Stage Development Antibodies; 4.5. Overview
Chapter 5: 5.1. Introduction; 5.2. Antibodies in Advanced Development; 5.4. Early-Stage Development Antibodies
Chapter 6: 6.1. Introduction; 6.2. Metabolic Disorders; 6.3. CNS Disorders; 6.4. Infectious Diseases; 6.5. Other Indications
Chapter 7
EMERGING NEW TECHNOLOGIES: 7.1. Introduction; 7.2. Modified Antibodies; 7.3. Antibody Engineering; 7.4. Therapeutic Profile Enhancements
Chapter 8
MAJOR COMPANIES: 8.1. Introduction; 8.2. The Key Players; 8.3. Other Companies; 8.4. Response of Other Major Pharma
Chapter 9
TECHNOLOGY-FOCUSED COMPANIES
Introduction: 9.1. Adimab; 9.2. Alder Biopharmaceuticals; 9.3. Biosynexus; 9.4. Celldex Therapeutics; 9.5. GANYMED Pharmaceuticals; 9.6. Genmab; 9.7. Human Genome Sciences; 9.8. ImmunoGen; 9.9. Innate Pharma; 9.10. MorphoSys; 9.11. Morphotek; 9.12. PanGenetics; 9.13. PDL BioPharma; 9.14. Perseis Therapeutics; 9.15. Seattle Genetics; 9.16. ToleRx; 9.17. Trillium Therapeutics; 9.18. TRION; 9.19. UCB; 9.20. Wilex; 9.21. XOMA
Chapter 10
COMMERCIAL OUTLOOK: 10.1. General Perspective; 10.2. Market Development; 10.3. Threats; 10.4. Overall Outlook
Figures and Tables: Figure 1.1. Schematic Structure of an Antibody; Figure 2.1. Progression in the Development of Therapeutic Monoclonal Antibodies; Figure 3.1. Accelerating Rate of US Approvals of Monoclonal Antibodies, 1986-2010; Figure 5.1. Antibodies in Development for Inflammatory & Autoimmune Disorders by Indication; Figure 8.1. 2009 Monoclonal Antibody Sales: Market Share by Company; Figure 10.1. Generic SWOT Analysis for Monoclonal Antibodies; Figure 10.2. Anticipated Approval Dates For New Monoclonal Antibodies, 2011-2015; Table 2.1. Marketed Monoclonal Antibodies by Type; Table 3.1. Reported 2009 Sales of Approved Monoclonal Antibodies; Table 3.2. Differentiation of the Approved Anti-TNF Antibodies; Tables 4.1-4.15. Monoclonal Antibodies in Clinical Development for Oncology Indications; Tables 5.1-5.3. Monoclonal Antibodies in Clinical Development for Inflammatory & Autoimmune Indications; Table 6.1-6.4. Monoclonal Antibodies in Clinical Development for Metabolic, CNS,Infectious Disease, Cardiovascular, and Other Indications; Tables 8.1-9.16. Company Antibody Development Pipelines

Monoclonal Antibodies: A Segment of Major Growth

Share this report

Other tasks

Research Assistance

Related Markets

Antibody Technologies Reports

Free Alert Me service